VZVadim M. Zabelin

Vadim M. Zabelin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vadim M. Zabelin has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy of combination immunotherapy in patients with generalized uveal melanoma: real clinical practice

    by A. V. Sultanbaev, I. A. Tuzankina, A. F. Nasretdinov, N. I. Sultanbaeva, K. V. Menshikov, Sh. I. Musin, V. M. Zabelin, R. T. Ayupov, V. E. Askarov, R. R. Rakhimov, et al.

    Introduction. Uveal melanoma is a rare malignant neoplasm that develops from melanocytes of the choroid of the eyeball. It occupies a leading position in the structure of intraocular malignant neoplasms.Aim. Тo analyze real-world clinical practice data on the use of nivolumab in combination with ipilimumab to treat patients with metastatic uveal melanoma.Materials and methods. Fifteen patients with metastatic uveal melanoma received therapy with nivolumab and ipilimumab. The median age of patients was 53 years, the minimum age was 24 years, and the maximum was 71 years. The analysis included 9 (60%) men and 6 (40%) women. Evaluation of the functional status showed that 4 (26.7%) patients had ECOG 0 points, 6 (40%) – ECOG 1 and 5 (33.3%) – ECOG 2.Results. The median relapse-free survival after enucleation of the eye was 61 months. Objective response to immunotherapy was achieved in 33.3% of patients, and the disease control rate was 86.6%. However, 4 (26.6%) patients discontinued therapy due to hepatotoxicity. The study noted that the median overall survival from the start of therapy with nivolumab in combination with ipilimumab reaches 8 months. It was found that the functional status of patients and the response to therapy are important predictors of survival, where patients with better indicators have a significantly higher life expectancy. Thus, patients with ECOG 0 show a median overall survival of 18 months.Conclusion. Immune checkpoint inhibitors remain the mainstay of treatment for patients with metastatic uveal melanoma. Combined immunotherapy with nivolumab and ipilimumab can be considered as a possible treatment option for this category of patients in conditions of limited therapeutic options.

  • Open Access

    Palbociclib in real clinical practice: Results of a single-center observational study

    by A. V. Sultanbaev, I. V. Kolyadina, A. F. Nasretdinov, K. V. Menshikov, V. E. Askarov, Sh. I. Musin, K. T. Akhmetgareeva, N. I. Sultanbaeva, V. M. Zabelin, R. T. Ayupov, et al.

    Introduction. A breakthrough in the treatment of metastatic hormone-dependent (HR+) breast cancer was combination endocrine therapy with CDK4/6 inhibitors, which significantly prolonged the tumor response time to treatment and the median survival before progression. The effectiveness of combination endocrine therapy in real-life practice is of particular interest due to the wider population of patients with different somatic status and comorbidity, often not included in randomized trials.Aim. Analyze of palbociclib using for treating patients with HR+/HER2– advanced breast cancer (mBC) at the Republican Clinical Oncology Dispensary.Materials and methods. Data from 323 patients were analyzed. Our study examined the effectiveness of combination endocrine therapy with palbociclib in patients with metastatic HR+ HER2– breast cancer. Data on the clinicopathological characteristics of patients and disease progression during palbociclib administration were obtained by reviewing clinical data from patient records and radiological/pathological examination reports.Results. The median age of patients included in the study was 62 years. When assessing the antitumor response, a partial response was recorded in 54 patients (16.7%), stabilization in 212 patients (65.6%), and progression in 57 patients (17.8%). The median progression-free survival was 13 months. Grade 3 adverse events were noted in 23 patients: neutropenia in 21.7% of cases, hepatotoxicity in 47.8% of cases, cardiotoxicity in 17.4% of cases, and coagulopathy in 4.3%. No patient discontinued therapy due to adverse events. The best treatment results were achieved by patients who used the combination of palbociclib with an endocrine partner as the first line of treatment for advanced stage.Conclusion. This analysis of real-world data on the use of palbociclib in real-world clinical practice confirms the RCT data on the efficacy and safety of using CDK4/6 inhibitors for the treatment of patients with HR+ HER2- mBC.


  • Open Access

    The use of ribociclib in real clinical practice: results of a single-center observational retrospective study

    by A. V. Sultanbaev, I. V. Kolyadina, Sh. I. Musin, A. F. Nasretdinov, N. I. Sultanbaeva, K. V. Menshikov, I. A. Menshikova, V. E. Askarov, R. R. Rakhimov, D. O. Lipatov, et al.

    Introduction. The standard initial treatment for patients with hormone receptor positive, HER2 negative, metastatic breast cancer (HR+/HER2– mBC) involves the use of CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy. The combination therapy has proven effectiveness in numerous Phase II and III randomized controlled trials (RCTs). Nonetheless, RCTs may not fully represent real-world clinical situations due to their stringent inclusion criteria, resulting in a specific patient population.Aim. Analyze of ribociclib using for treating patients with HR+/HER2– advanced breast cancer (mBC) at the Republican Clinical Oncology Dispensary.Materials and methods. Patients diagnosed with HR+/HER2– mBC who were treated in clinical routine with ribociclib in combination with different endocrine agents between 2016 and 2020 were identified and enrolled in this retrospective study. Clinicopathological characteristics and clinical outcomes were recorded with particular emphasis on ribociclib therapy course (progression-free survival (PFS), toxicity, dose reduction).Results. Data from n = 101 patients were evaluated. The mean patient age was 61 years. The study included 67 (66.3%) patients with progression after radical treatment and 34 (33.7%) patients with primary disseminated breast cancer. Dose reduction due to adverse events was performed in n = 14 cases (13.9%). Presence of prior therapy lines and lower ECOG status were associated with shorter PFS, whereas estrogen positivity and the choice of fulvestrant over aromatase inhibitor were positively associated with PFS. Metastatic pattern, progesterone positivity and dose reduction due to toxicity did not significantly impact on PFS.Conclusion. Our real-world data analysis on ribociclib treatment in Russian regional hospital supports data from RCTs regarding both treatment efficacy and safety of CDK4/6i for treatment of patients with HR+/HER2– mBC. Currently, by expanding our experience with CDK4/6 inhibitors in different groups of patients with mBC, we will be able to provide patients with optimal treatment options.

  • Treatment of Metastatic Renal Cell Carcinoma with Checkpoint Inhibitors in Clinical Practice in the Volga-Ural Region of the Eurasian Continent

    by Radmir R. Rakhimov, Aleksandr V. Sultanbaev, Konstantin V. Menshikov, Vadim M. Zabelin, Gulshat R. Gilyazova, Svetlana M. Izmailova, Ksenia S. Bakhtiyarova, Angelina A. Izmailova, Irina R. Gilyazova

    Introduction: Renal cancer ranks 10th in the mortality structure of the Russian Federation. The introduction of checkpoint inhibitors has changed the paradigm of treatment of patients with malignant neoplasms. Method: Data from clinical trials have shown good progression-free median and median overall survival. Each cancer center has been accumulating its own experience in treating patients with renal cell cancer by applying modern target drugs and immunotherapy. Result: In routine clinical practice, oncologists do not get the results that have been demonstrated in clinical trials when evaluating the effectiveness of the therapy. Conclusion: In this single-center clinical study, we discuss the results of using nivolumab as mono-therapy and the combination of nivolumab with ipilimumab in metastatic renal parenchyma cancer patients.


  • Open Access

    Resistance to immune checkpoint inhibitors in the treatment of metastatic renal cancer

    by A. A. Izmailov, R. R. Rakhimov, A. V. Sultanbayev, K. V. Menshikov, I. R. Gilyazova, V. M. Zabelin

    Over the past 5 years, checkpoint inhibitors including anti-CTLA-4 and anti-PD-1/PD-L1 blockers have changed approaches to therapy of metastatic renal cell cancer. However, more than 55 % of patients with advanced kidney cancer remain resistant to immunotherapy. This paper refects the causes that lead to primary and acquired resistance to immune checkpoint inhibitors during the treatment of metastatic renal cell cancer. The purpose of the study was to elucidate the mechanisms underlying resistance to checkpoint inhibitors during the treatment of metastatic kidney cancer. Material and Methods. A literature search was conducted using Pubmed database in the time interval between 2010 and 2023. We identifed 286 publications of which 59 were relevant for our review. Results. There are many factors that contribute to primary or acquired resistance to immunotherapy, including factors associated with the tumor cell as well as tumor microenvironment factors. Conclusion. Many innovative approaches to overcoming resistance to monoclonal antibodies are being investigated in clinical trials. In connection with the advent of new methods, the cellular composition of the tumor microenvironment and its role in the emergence of tumor resistance to immunotherapy are becoming increasingly clear. New biomarkers are emerging to help identify the best candidates for immunotherapy in metastatic kidney cancer. However, they require further study.